MedDataX Logo

Efficacy and Saftey Study of 99mTc-ECDG in the Evaluation of Coronary Artery Disease (CAD)

NCT01899833 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-04-01

No results posted yet for this study

Summary

This study will compare how well a new radiolabeled imaging agent ECDG compares to the current testing for coronary artery disease (radiolabeled Sestamibi) during a rest and stress cardiac test as documented from results of a coronary angiogram (if performed).

Conditions

  • Coronary Artery Disease

Interventions

DIAGNOSTIC_TEST

99mTc-Sestamibi

An injection of 99mTC-Sestamibi will be administered by IV push under medically observed conditions.

Sponsors & Collaborators

  • Cell>Point LLC

    lead INDUSTRY

Principal Investigators

  • Gary Heller, MD · Consultant

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-10
Primary Completion
2025-12-31
Completion
2026-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01899833 on ClinicalTrials.gov